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A new series of novel 3-(5-aryl/aryloxy methyl-1,3,4-thiadiazol-2-yl)-spiro-cyclohexane-1'2-thiazolidin-4-ones have 
been synthesized from a common intermediate, in good yields. These compounds have been screened for their antibacterial 
and antifungal activity against different pathogenic strains of bacteria and fungi. The minimum inhibitory concentration 
(MIC) and minimum bactericidal concentration (MBC) have been determined for the test compounds as well as for 
reference standards. Compounds 3c, 3d, 6c and 6d have shown good antibacterial activity where as compounds 3a, 3b, 6a 
and 6b have displayed better antifungal activity. 
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One of the major problems facing humanity today in the 
context of life-threatening diseases such as microbial 
infections, tuberculosis, cancer, HIV/AIDS, influenza, 
rotavirus, cardiovascular and malaria disease is the 
relentless increase and spread of multidrug-resistant 
microbes. Thus, studies for the identification of novel 
targets and drugs for the treatment of infectious diseases 
are at the forefront. Since last two decades, several 
heterocyclic compounds from the series of thiazolidinone 
were synthesized and their pharmacological activity has 
consequently been investigated. 
Moreover, thiazolidinones analogs were also 
considered as important biologically active scaffolds
1
. 
Thiazolidin-4-ones contain β-lactam ring with sulphur 
atom in the ring. Their derivatives interact with Mur 
B enzyme and inhibit the biosynthesis of the 
peptidoglycan polymer essential for cell wall of 
bacteria
2
. Thiazolidinone also have some significant 





























 activity, etc. 
1,3,4-Thiadiazoles are a class of heterocyclic 
which have attracted significant interesting medicinal 
chemistry and they have a wide range of 












agents. The spiro 
carbon induces a relatively large steric strain and 
hence undergoes rearrangement reactions yielding to 
unexpected heterocycles
29
. A large number of spiro 
heterocyclic compounds were prepared
30




In light of above literature and abundance on 
bio-potentials of spiro heterocyclic analogues, we 
designed two or more different heterocyclic moieties 
in a single molecule and were confident that there 
framework would provide the important structural 
motifs for the discovery of new antimicrobial agents. 
In continuation of our research on efficient synthesis 
of biologically active small molecules
32,34
, we 
developed spiro-cyclohexane derivatives containing 
1,3,4-thiadiazole demonstrated their antimicrobial 
activity. The structures of these compounds was 
established by the IR, 
1
H NMR spectral data and 
elemental analysis (Scheme I). 
A plausible mechanism for the formation of titled 
3-(5-aryl/aryloxymethyl-1,3,4-thiadiazol-2-yl)-spiro-
cyclohexane -1’,2- thiazolidin-4-ones scaffold is 
given in Scheme II. 
The required starting material 2-amino-5-
substituted aryl/aryloxymethyl-1,3,4-thiadiazole 1 and 




4 was prepared by the known method
35
. A mixture  
of phenyl thio-semicarbazide/phenoxyacetothio-
semicarbazide was stirred in conc. H2SO4 below 15°C 
to stand for an hour and then poured into cold water. 
The product which was precipitated on neutralization 
with ammonia solution was filtered washed with 
water and recrystallized from ethanol to furnish the 
corresponding thiadiazole derivatives. 
 
Antimicrobial Activity 
The synthesized pure compounds were screened for 
antibacterial and antifungal activities adopting 
standard protocols
36
. The antibacterial activity of 
prepared final pure compounds 3a-d and 6a-d was 
performed against Staphylococcus aureus, Bacillus 
subtilis, Escherichia coli and Klebsiella pneumoniae 
using ciprofloxacin as positive and DMSO as negative 
control. Minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) were 
determined and the activity was reported in μg/mL. 
The nutrient broth, which contained logarithmic 
serially two fold diluted amount of test compounds 
and controls were inoculated with approximately 
5×10
5 













The cultures were incubated for 24h at 37°C  
and the growth was monitored visually and 
spectrophotometrically. The antibacterial results were 
summarized in Table I where compound 3c showed 
moderate activity against gram-positive bacteria  
S. aureus and B. subtilis where as 6c and 6d were 
active against gram-negative K. pneumoniae ranging 
from 30 to 50 μg/mL concentration and only  
one compound 3d was found active against E. coli 
25 μg/mL concentration. MBC/MIC ratio of all active 
compounds is ranging from 2.0 to 3.3 suggesting 
these compounds are bactericidal not bacteriostatic. 
Antimicrobial agent is considered bacteriostatic when 
the minimal MBC/MIC ratio is greater than or equal 
to 8 whereas it is considered bactericidal if MBC/MIC 
ratio is less than or equal to 4. 
 
Fungicidal Activity 
The antifungal activity, of the prepared pure 
compounds was performed against Tilletia indica, 
Trichoderma, P. cubensis, S. fuliginea and P. 
infestans using Griseofulvin as positive and  
DMSO as negative control. Minimum inhibitory 
concentration (MIC) was determined and reported in 
μg/mL. Antifungal activity was carried out through 
disk diffusion method
37
. All fungal cultures were 
routinely maintained on Sabouraud dextrose agar 
(SDA) and incubated at 28ºC. The antifungal 
activities are summarized in Table II, only for those 
compounds which were found active against any of 
these strains of fungi. It is inferred from Table II that 
compounds 3a, 3b, 6a, 6b showed antifungal activity 
against T. indica, Trichoderma, P. cubensis, S. 
fuliginea and P. infestans strain of fungi ranging from 
10 to 20 μg/mL in concentration which is comparable 
to Griseofulvin. 
The structure – activity relationship (SAR) of the 
tested compounds for antimicrobial activity can be 
summarized as follows 
(i) In the series of compounds 3a-d and 6a-d the 
substitution at phenyl/phenoxymethyl ring and 
presence of 1,3,4- thiadiazole with spiro-
cyclohexane and thiazolidin-4-ones moiety is an 
important scaffold for better antibacterial as well 
as antifungal activity. 
(ii) Most of the antibacterial compounds have 
MBC/MIC ratio below 4, it means they are 
bactericidal not bacteriostatic, Antifungal activity 
of these compounds was similar or even better in 
some cases as comparable to Griseofulvin, a 
known antifungal agent. The possible mechanism 
for the antibacterial activity of examined 
Table I — Antibacterial activity of compounds possess promising biological activity 
Compd Gram-positive bacteria Gram-negative bacteria 
S. aureus B. subtilis E. coli K pneumonia 
MIC MBC MIC MBC MIC MBC MIC MBC 
3c 30 100 20 50 n.a. n.a. n.a. n.a. 
3d n.a. n.a. n.a. n.a. 25 50 n.a. n.a. 
6c n.a. n.a. n.a. n.a. n.a. n.a. 25 50 
6d n.a. n.a. n.a. n.a. n.a. n.a. 25 50 
Ciprofloxacin 6.5 12.5 10.0 25 6.25 25 6.25 10.25 
DMSO n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
MIC (μg/mL), minimum inhibitory concentration i.e. the lowest concentration of the compound to inhibit growth of bacteria completely, 
MBC (μg/mL) minimum bacterial concentration i.e. the lowest concentration of the compound for killing the bacteria completely, 
MBC/MIC ratio are against-S. aureus(3c, 3.3), B. subtilis(3c, 2.5), E. coli (3d, 2.0) and K. pneumoniae (6c, 2.0, 6d, 2.0), n.a.- no activity 
detected. 
 
Table II — Antifungal activity of compounds 3a, 3b, 6a and 6b 
Compd Fungal species and MIC (μg/mL) 
T. indica Trichoderma P. cubensis S. fuliginea P. infestans 
3a 20 15 13 16 15 
3b 178 13 14 14 17 
6a 12 10 11 10 10 
6d 17 15 13 10 15 
Griseofulvin 20 18 16 18 20 
DMSO n.a. n.a. n.a. n.a. n.a. 
MIC (𝜇g/mL), minimum inhibitory concentration i.e. the lowest concentration of the compound to inhibit the growth of fungi. 
n.a. – n o activity detected. 




compounds is not known at the moment and 
investigations are being done to investigate the 
mechanism of antibacterial action, and to 
synthesize more effective compounds. 
 
Experimental Section 
Melting points were recorded in Richerf 
Thermover instrument and are uncorrected. The IR 
spectra was recorded on Perkin-Elmer RXI 




C NMR were recorded 
on Bruker-300 and Bruker Avance II 400 spectrometers 
using tetramethylsilane (TMS) as an internal standard 
and DMSO-d6/CDCl3 as solvent. The Micro analytical 
data were collected on Elemental Vario EL III 
elemental analyzer. All chemicals used were 
purchased from Merck and Fluka Chemicals.  
The homogeneity of compounds was checked  
by thin layer chromatography (TLC) on glass  
plates coated with silica gel G254 (Merck, Mumbai, 
India) using chloroform-methanol (3:1) mixture as 
mobile phase. 
 
General procedure for synthesis of 3- (5 – 
substitutedphenyl-1,3,4-thiadiazol-2-yl)-spiro-
cyclohexane-1',2- 
thiazolidin -4-ones (R=H) 
A mixture of 2-[cyclohexylidene] amino-5-phenyl -
1,3,4- thiadiazole (0.01 mol) and mercaptoacetic acid 
(1.0 mL) was refluxed in dioxane (25.0 mL) for 2-3 h. 
Excess of solvent was removed and resulting mass 
was poured into cold water and neutralized from 
sodium bicarbonate solution. The solid product 
obtained was filtered and washed with water and 
recrystallized from aqueous ethanol to get crystalline 
solid products 3a-d. 
 
3a: Colourless solid. Yield 70%. m.p.159°C. IR: 
3050 (C-H arom), 2950 (C-H alip), 1710 (C=O), 1664 




H NMR (DMSO-d6): δ 7.41-8.09 (m, 5 H arom. 
proton), 3.33-2.12 (d 2H thiazolinone ring proton), 
1.75-2.12 (m,5H, cyclohexane ring); 
13
C NMR 
(DMSO-d6): δ 23.2, 103.3, 113.1, 122.5, 125.9, 139.6, 
140.7, 144.5, 148.5, 161.9, 163.3, 168.7, 168.0, 169.2, 
170.9. 
 
3b: Colourless solid. Yield 68%. m.p.90°C. IR: 
3057 (C-H arom), 2942 (C-H alip), 1718 (C=O), 1654 





(DMSO-d6): δ 7.56-8.39 (m, 4 H arom. proton), 3.33-
2.12 (d 2H thiazolinone ring proton), 1.75-2.12 
(m,5H, cyclohexane ring); 
13
C NMR (DMSO-d6): δ 
23.4, 104.3, 112.1, 122.8, 126.0, 138.3, 140.5, 143.2, 
147.6, 160.9, 163.8, 167.2, 168.4, 169.8, 171.9, 172.7. 
 
3c: Colourless solid. Yield 68%. m.p.165°C. IR: 
3225 (O-H Streaching), 3048 (C-H arom), 2946  





H NMR (DMSO-d6): δ 9.25  
(s, 1 H OH Proton), 7.66-8.40 (m, 4 H arom. proton), 
3.33-2.12 (d 2H thiazolinone ring proton), 1.75-2.12 
(m,5H, cyclohexane ring); 
13
C NMR (DMSO-d6):  
δ 25.4, 105.2, 110.3, 120.8, 126.6, 137.5, 141.8, 
144.6, 148.5, 162.8, 164.6, 167.9, 169.2, 171.4,  
172.6, 174.9. 
 
3d: Colourless solid. Yield 68%. m.p.120°C. IR: 
3050 (C-H arom), 2952 (C-H alip), 1720 (C=O),  




H NMR (DMSO-d6): δ 7.54-8.29 (m, 4 H arom. 
proton), 3.33-2.12 (d 2H thiazolinone ring proton), 
1.75-2.12 (m,5H, cyclohexane ring); 
13
C NMR 
(DMSO-d6):δ 23.3, 105.8, 111.0, 122.4, 127.5,  
136.3, 142.4, 145.8, 149.3, 160.2, 164.3, 166.4, 169.5, 
171.8, 173.7, 172.4. 
 
General procedure for synthesis of 3- (5 – substituted 
phenoxymethyl-1,3,4-thiadiazol-2-yl)-spiro-
cyclohexane-1',2-thiazolidin -4-ones (R=H) 
A mixture of 2-[cyclohexylidene]- amino-5-
phenoxymethyl -1,3,4- thiadiazole (0.01 mol) and 
mercaptoacetic acid (1.0 mL) was refluxed in dioxane 
(25.0 mL) for 2-3h. Excess of solvent was removed 
and resulting mass was poured in to cold water and 
neutralized from sodium bicarbonate solution. The 
solid product obtained was filtered and washed with 
water and recrystallized from aqueous ethanol to get 
crystalline solid products 6a-d. 
 
6a: Colourless solid. Yield 70%. m.p.185°C. IR: 
3054 (C-H arom), 2960 (C-H alip), 1725 (C=O),  




H NMR (DMSO-d6): δ 7.48-8.19 (m, 5H arom. 
proton), 4.03 (d, 2H –OCH2 proton), 3.33-2.12  
(d2H thiazolinonering proton), 1.75-2.12 (m,5H, 
cyclohexane ring); 
13
C NMR (DMSO-d6): δ 23.2, 
103.3, 106.2, 110.2, 113.1, 122.5, 125.9, 139.6,  
140.7, 144.5, 148.5, 161.9, 163.3, 168.7, 168.0,  
169.2, 170.9. 
 
6b: Colourless solid. Yield 68%. m.p.165°C. IR: 
3060 (C-H arom), 2945 (C-H alip), 1720 (C=O),  




H NMR (DMSO-d6): δ 7.51-8.37 (m, 4 H arom. 




proton), 4.03 (d, 2H –OCH2 proton),3.33-2.12  
(d2H thiazolinonering proton), 1.75-2.12 (m,5H, 
cyclohexane ring); 
13
C NMR (DMSO-d6):δ 23.4, 
104.3,, 107.0, 112.1, 122.8, 126.0, 138.3, 140.5, 
143.2, 147.6, 160.9, 163.8, 167.2, 168.4, 169.8, 171.9, 
172.7. 
 
6c: Colourless solid. Yield 68%. m.p.145°C. IR: 
3225 (O-H Streaching), 3048 (C-H arom), 2946 (C-H 





H NMR (DMSO-d6): δ 9.25  
(s, 1 H OH Proton), 7.58-8.43 (m, 4 H arom. proton), 
4.03 (d, 2H –OCH2 proton), 3.33-2.12  
(d2H thiazolinonering proton), 1.75-2.12 (m,5H, 
cyclohexane ring); 
13
C NMR (DMSO-d6): δ 25.4, 
105.2, 107.2,110.3, 120.8, 126.6, 137.5, 141.8,  
144.6, 148.5, 162.8, 164.6, 167.9, 169.2, 171.4,  
172.6, 174.9. 
 
6d: Colourless solid. Yield 68%. m.p.110°C. IR: 
3050 (C-H arom), 2952 (C-H alip), 1720 (C=O), 1650 





(DMSO-d6): δ 7.46-8.28 (m, 4 H arom. proton),  
4.03 (d, 2H –OCH2 proton), 3.33-2.12 (d2H 
thiazolinonering proton), 1.75-2.12 (m,5H, 
cyclohexane ring); 
13
C NMR (DMSO-d6): δ 23.3, 
105.8, 108.0,111.0, 122.4, 127.5, 136.3, 142.4,  




In the present investigation, a series of new 
spiroheterocycles have been synthesized and screened 
for their antifungal and antibacterial activity. The 
activity reveals that the synthesized compounds 
possess moderate to good activity profile. The 
insights gained in this study will be useful for 
development of new anti-infective agents. 
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